Another CB1 Weight Loss Drug

It seems that everyone is jumping on the weight loss drug bandwagon these days and researching and financing weight loss medicines that work in the same way as the Acomplia drug does. We already have stories about the fact that both Merck, (who make Propecia the hair loss drug), and Pfizer (who make the erectile dysfunction drug Viagra) are busy with clinical trials for their weight loss drugs but now we have news that a smaller Belgium company called Solvay is pushing ahead with its work on the Phase II clinical testing for the SLV319 weight loss drug.

In the agreement that it has with its business partner, Solvay will be getting 25 million dollar research and development payment from Bristol-Myers Squibb Co. who agreed to help finance the drug if preliminary testing shows good results.
Solvay have released a statement explaining that in the testing so far the SLV319 drug worked well on the cannabinoid type 1 or CB1 receptors that control cravings for food and make people eat too much. This is exactly what the Acomplia drug does and why it works so well on obese and overweight people.

A weight loss drug that works by convincing people that they are not hungry and that they do not want to eat is the drug that every drug Company wants to find. So far there have been notable successes with both the Reductil and Acomplia weight loss drugs but both come with side effects that make them unsuitable for some people. To find a weight loss drug that would work completely safely and with no side effects would be worth billions to any drug company.

Sanofi Aventis are hoping that when the approval for the weight loss drug Acomplia comes through from America’s FDA that sales should hit three billion dollars each year.